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Abstract: Marine organisms are a rich source of biologically active lipids with anti-inflammatory
activities. These lipids may be enriched in visceral organs that are waste products from common
seafood. Gas chromatography-mass spectrometry and fatty acid methyl ester (FAME) analyses
were performed to compare the fatty acid compositions of lipid extracts from some common
seafood organisms, including octopus (Octopus tetricus), squid (Sepioteuthis australis), Australian
sardine (Sardinops sagax), salmon (Salmo salar) and school prawns (Penaeus plebejus). The lipid
extracts were tested for anti-inflammatory activity by assessing their inhibition of nitric oxide (NO)
and tumor necrosis factor alpha (TNFα) production in lipopolysaccharide (LPS)-stimulated RAW
264.7 mouse cells. The lipid extract from both the flesh and waste tissue all contained high amounts
of polyunsaturated fatty acids (PUFAs) and significantly inhibited NO and TNFα production. Lipid
extracts from the cephalopod mollusks S. australis and O. tetricus demonstrated the highest total
PUFA content, the highest level of omega 3 (ω-3) PUFAs, and the highest anti-inflammatory activity.
However, multivariate analysis indicates the complex mixture of saturated, monounsaturated, and
polyunsaturated fatty acids may all influence the anti-inflammatory activity of marine lipid extracts.
This study confirms that discarded parts of commonly consumed seafood species provide promising
sources for the development of new potential anti-inflammatory nutraceuticals.
Keywords: seafood waste; polyunsaturated fatty acid; NO inhibition; fish oil; marine nutraceuticals
1. Introduction
Acute and chronic inflammation is the basis of many serious diseases including asthma,
cardiovascular diseases, and rheumatoid arthritis [1]. The stimulation of macrophages during the
inflammatory response gives rise to overproduction of several pro-inflammatory mediators, including
nitric oxide (NO) via inducible nitric oxide synthase (iNOS) [2]. NO overproduction can lead to tissue
damage through cytokine-mediated processes. This molecule can also cause vasodilation, edema,
and cytotoxicity [3,4]. Macrophage stimulation also leads to the overproduction of many cytokines
including TNFα and interleukins (IL). These pro-inflammatory cytokines have many roles, including
the recruitment and activation of more macrophages, effects on the endothelial cells in the blood
vessels, as well as playing a role in the perception of pain generated from inflammation [5]. Cytokines
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such as TNFα are powerful pro-inflammatory mediators during infection, trauma, or surgery, which
can trigger short- and long-term effects on the peripheral and central nervous system, leading to
exacerbated pain processed by directly affecting specific receptors on sensorial neurons [6,7]. Thus,
these pro-inflammatory cytokines and NO are reliable markers for screening new anti-inflammatory
treatments in vitro and in vivo.
The conventional management of inflammation relies mainly on the use of steroidal and
non-steroidal anti-inflammatory drugs (NSAIDs). Both drug families are well-known for their common
and serious side effects [8], especially when associated with long term consumption, such as is often
required for the treatment of chronic inflammatory diseases. Consequently, there is a critical need to
identify new sources of less harmful treatments, particularly for the management of diseases associated
with chronic inflammation. Our increased understanding of the impact of food and diet on health has
driven the search for novel natural medicines [9]. A recent study has shown that patients suffering
from chronic inflammatory diseases are more likely to seek out natural anti-inflammatory agents with
the intention to minimize the side effects associated with long term use of steroid and NSAIDs [8].
Therefore, the development of new safer anti-inflammatory nutraceuticals is of clinical interest and
could have a significant impact on the treatment of inflammatory cases. Functional foods and marine
extracts provide a relatively untapped source of potential anti-inflammatory agents, but claims need to
be evidence-based.
In comparison to saturated fats, dietary polyunsaturated fatty acids (PUFAs) can have a number
of positive impacts on health when incorporated into the diet to meet deficiencies from sub-optimal
dietary intake. The human body relies on food as a source of long chain PUFAs, as it is unable to
synthesize PUFAs larger than 18 carbons [10]. Both omega 3 (ω-3) alpha-linolenic and omega 6 (ω-6)
linoleic PUFAs are considered essential for mammals and can only be obtained from the diet. Seafood
(fish and shellfish) lipids are the main sources of biologically activeω-3 long chain PUFAs [10,11]. These
PUFAs are known to minimize the occurrence and severity of chronic inflammatory conditions [12–15],
cancer [16–18], obesity [19,20], and cardiovascular diseases [10,21,22]. Dietary PUFAs have been
shown to improve the quality of life for people suffering from chronic inflammatory diseases such as
arthritis, asthma, and neuroinflammatory diseases [11]. Long chain ω-3 PUFAs can directly inhibit
inflammation by competing with arachidonic acid or indirectly by affecting the transcription factors or
nuclear receptors responsible for inflammatory gene expression [23].
Docosahexaenoic acid (C22:6ω-3) (DHA) and eicosapentaenoic acid (C20:5ω-3) (EPA) are the
most valuable long chain PUFAs and are considered potent anti-inflammatory agents as a result of
the amount and type of the eicosanoids they generate, which interfere with intracellular signaling
pathways, transcription factors, and gene expression mechanisms [24]. DHA has been shown to
reduce the levels of IL-1β and TNFα in LPS-stimulated peripheral blood mononuclear cells (PBMNC)
in vitro [25]. Furthermore, studies have shown that a number of health problems including increased
inflammatory processes [26], poor fetal development, and a higher risk of Alzheimer’s diseases are
associated with diets low in EPA and DHA PUFAs [27].
Omega 3 PUFAs can be commercially sourced from oily fishes including salmon, sardine, and
mackerel [10]. There is some evidence that seafoods from temperate Australian origins contain
higher amounts of DHA compared to seafood from the northern hemisphere [28]. Some of the
PUFA-rich Australian marine organisms include crustaceans, such as school prawn and tiger prawn,
oily fishes such as sardine and salmon, and mollusks, including octopus, squid, shelled gastropods,
and bivalves [28]. In Western countries like Australia, there is a significant level of waste from
underutilization of parts of seafood, as only the choice flesh is consumed by many people. However,
valuable PUFAs might not only occur in the predominantly eaten components of the seafood
organisms, but could also be present in the undervalued presumptive waste tissues of fish and
shellfish. For example, in fish, lipids are not only stored in the subcutaneous tissue, belly flap, and
muscle, but are also high in mesenteric tissue, head, and liver [29]. A number of previous studies
have investigated the quality of fatty acids in seafood waste tissues. For example, high levels ofω-3
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rich PUFAs were found in lipid extracts from the head (26%), intestine (24%), and liver (23%) from
the sardine Sardinella lemuru [30], and similarly in the tuna Euthynnus affinis (head 28.77%; intestine
27.43%; liver 23.98%) [31]. Significant amounts of the valuable ω-3 EPA and DHA were also found
in eye orbital samples of tuna in an Australia-based study [28,32]. Therefore, the byproducts of the
seafood industry could be a source of high-quality anti-inflammatory fatty acids.
To date, investigations on the anti-inflammatory activity of fish oil have been insufficiently
investigated, and consequently, results remain inconclusive [33]. Nevertheless, there is some clinical
evidence to support the benefits of krill oil in the treatment of inflammatory conditions [34,35],
suggesting that the specific PUFA composition may be important for anti-inflammatory activity. Many
molluscan products and derivatives are used in traditional medicines for the treatment of inflammatory
conditions [36], and mollusks are also known to be rich in beneficial PUFAs [37]. Examples of lipid
extracts from mollusk with demonstrated in vivo and in vitro anti-inflammatory activity include the
New Zealand green-lipped mussel Perna canaliculus [38], Filopaludina bengalensis foot [39], Indian
green mussel Perna viridis [40,41], Mytilus unguiculatus (Hard-shelled mussel) [40], and sea hares
Aplysia fasciata and Aplysia punctata [42]. Despite the promising anti-inflammatory activity of lipid
extracts from mollusks, the only natural anti-inflammatory nutraceuticals available over-the-counter
as anti-inflammatory medications are Lyprinol and Biolane sourced from the lipid extract of the
New Zealand green-lipped mussel Perna canaliculus [38], and CadalminTM, the lipid extract from a
closely related species of bivalve Perna viridis in India [41,43]. The anti-inflammatory activities of lipid
extracts from predatory cephalopod mollusks are yet to be tested.
This study aims to investigate the composition of lipid extracts from common Australian seafoods
including oily fish, prawns, and cephalopods, with a comparison of the edible flesh and under-utilized
by-products. The anti-inflammatory activity of these lipid extracts was compared using in vitro assays
for NO and TNFα inhibition and the inhibition concentrations (IC50s) were correlated to the fatty acids
composition to provide further insight into how the fatty acid compositions of marine lipid extracts
influence the anti-inflammatory potential.
2. Results
2.1. Comparison of Fatty Acid Composition from Lipid Extracts of Different Seafood and Waste Products
As expected for oily fish, the highest yield of lipid extract was recovered from the Australian
sardine, followed by salmon (>100 mg/g tissue, Figure 1A). Substantially lower quantities were
recovered from the cephalopods and prawns (5–40 mg/100 g tissue, Figure 1A). Higher quantities of
oil were recovered from the viscera and/or heads of all species in comparison to the flesh. The lipid
extracts from the cephalopod mollusks had the highest proportion of PUFAs comprising over 40% of
the fatty acid composition (Figure 1B, Table 1). Salmon had the lowest percentage of PUFAs (<25%),
but the highest percentage of MUFAs, with over 45% of the total fatty acids (Figure 1B and Table 1).
Permutational analysis of variance (PERMANOVA) revealed a significant difference between species
in the composition of fatty acid classes (Pseudo F = 16.4, p = 0.001). Pair-wise analysis revealed that
the octopus, squid, prawns, and sardines were not significantly different in the relative proportion of
fatty acid classes (p > 0.05); however, salmon was significantly different to octopus (p = 0.0091), squid
(p = 0.0066) and sardines (p = 0.0017). Specifically, there were significantly less saturated fatty acids and
more monounsaturated fatty acids in salmon compared to squid (SFA p = 0.0035, MUFA, p = 0.0054)
and sardines (SFA p = 0.001, MUFA = 0.0031). Salmon had significantly less PUFAs than octopus
(p = 0.0144), squid (p = 0.0144), and sardines (p = 0.0202). The PUFAs were also significantly lower in
prawns compared to octopus (p = 0.0302) and squid (p = 0.0276). The waste products (viscera and
heads), did not have a significantly different profile to the more frequently consumed cephalopod flesh
or fish fillets, but the prawn heads and viscera had less MUFA, relative to SFA and PUFA, compared to
the body flesh (Figure 1B). All extracts had a healthyω-6/ω-3 ratio of less than or close to 1 (Table 1B),
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with the ratio as low as 0.1 in sardines and the flesh of octopus. The ratio of saturated to unsaturated
fatty acids was also less than 1 for all species.Mar. Drugs 2018, 16, x 4 of 19 
 
 
Figure 1. Lipid composition of some common Australian seafood flesh and waste streams: (A) The 
amount of oil extracted from the flesh (mg/g tissue); (B) the amount of the main fatty acid classes and 
other hydrocarbons (dimethyl acetal aldehydes) in the lipid extracts (mg/g oil). The fatty acids were 
quantified by GC-FID and identified against reference standards with supplementary GC-MS 
analyses. The samples are: Octopus tetricus flesh and viscera, Sepioteuthis australis (squid) flesh and 
head; Sardinops sagax (Australian sardine) flesh and viscera, including heads; Salmo salar (Atlantic 
salmon) flesh and head (SH); and Penaeus plebejus (Australian school prawn) flesh and head, including 
viscera. 
Multivariate comparison of the overall fatty acid profiles in the oil extracts revealed significant 
differences between the species (Pseudo-F = 9.59 p = 0.0007), but not between the different types of 
tissue (Pseudo-F = 2.73, p > 0.05), and there was no significant interaction between these factors 
(Pseudo-F = 1.6, p > 0.05). Pair-wise tests confirmed that S. salar (salmon) has a different fatty acid 
composition to all species except prawns (p < 0.01), which is driven by a higher percentage of oleic, 
linoleic, and eicosatrienoic acids in the salmon and prawn heads (Figure 2 and Table 1A). The squid 
contained higher proportions of stearic acid, arachidonic (ARA), and docosahexaenoic acid (DHA), 
and were significantly different to sardines (p = 0.015), which, along with octopus and prawn bodies, 
have a higher percentage of the SFA arachidic and the ω-3 PUFA, EPA (Figure 2). 
Figure 1. Lipid composition of some common Australian seafood flesh and waste streams: (A) The
amount of oil extracted from the fles g tissue); (B) the amount of the main fatty acid classes
and other carbons (dimethyl acetal aldehydes) in the lipid extracts (mg/g oil). The fatty acids
were antified by C-FID and identified against r f rence standards with supplementary GC-MS
analyses. The samples are: Octopus tetricus flesh and viscera, Sepioteuthis australis (squid) flesh and head;
Sardinops sagax (Australian sardine) flesh and viscera, including heads; Salmo salar (Atlantic salmon)
flesh and head (SH); and Penaeus plebejus (Australian school prawn) flesh and head, including viscera.
Multivariate comparison of the overall fatty acid profiles in the oil extracts revealed significant
differences between the species (Pseudo-F = 9.59 p = 0.0007), but not between the different types
of tissue (Pseudo-F = 2.73, p > 0.05), and there was no significant interaction between these factors
(Pseudo-F = 1.6, p > 0.05). Pair-wise tests confir ed that S. salar (salmon) has a different fatty acid
compositi n t all speci s xcept prawns (p < 0. ich is driven by a higher percentage of oleic,
linole c, and eicosatrienoic a ids in the salmon a n heads (Figure 2 and Table 1A). The squid
contained higher pro ortions of stearic acid, arac i o ic (ARA), an docosahexaenoic acid (DHA),
and were significantly different to sardines (p = 0.015), which, along with octopus and prawn bodies,
have a higher percentage of the SFA arachidic and theω-3 PUFA, EPA (Figure 2).
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Figure 2. Principal coordinate ordination (PCO) of the fatty acid composition of various Australian 
seafood species. Vector overlay based on the Pearson correlation (r > 0.8) identifies the main fatty 
acids contributing to the separation between extracts, with higher levels of the specifically labeled 
fatty acids occurring in samples in the direction of the vector. 
The amounts of EPA, DPA, and DHA per 100g of the seafood tissue were estimated from the 
yield of oil in the original tissue (Table 1B). Due to high oil yields, the sardines were the best source 
of these ω-3 PUFAs, with a total amount of over 3500mg/100g tissue in the flesh and over 6000 mg/100 
g in the viscera. The viscera of octopus and heads of salmon also had high ω-3 yields with totals of 
over 1000mg/100g tissue. In all species, the viscera and/or head waste streams produced larger 
amounts of EPA, DPA, and DHA (Table 1B). 
2.2. Cytotoxicity 
At 50 µg/mL, none of the seafood extracts caused any reduction in cell viability for either 3T3-
ccl-92 fibroblasts or RAW 264.7 macrophages (Table 2).  
Figure 2. Principal coordinate ordination (PCO) of the fatty acid composition of various Australian
seafood species. Vector overlay based on the earson correlation (r > 0.8) identifies the main fatty acids
contributing to the separation between extracts, with higher levels of the specifically labeled fatty acids
occurring in samples in the direction of the vector.
The amounts of EPA, DPA, and DHA per 100g of the seafood tissue were estimated from the yield
of oil in the original tissue (Table 1B). Due to high oil yields, th sardine w re th best source of these
ω-3 PUFAs, with a total mount of ov r 3500mg/100g tissue n the flesh and over 6000 mg/100 g in
the viscera. The viscera of octopus and heads of salmon also had highω-3 yields with totals of over
1000mg/100g tissue. In all species, he viscera and/or he d waste stre ms produced larger amounts of
EPA, DPA, and DHA (Table 1B).
2.2. Cytotoxicity
At 50 µg/mL, none of the seafood extracts caused any reduction in cell viability for either
3T3-ccl-92 fibroblasts or RAW 264.7 macrophages (Table 2).
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Table 1. Fatty acid profiles of lipid extracts from the commonly consumed flesh (tentacles, fillet, body) and waste products (viscera, heads) of Australian seafood
organisms: (A) µg fatty acid per mg oil extract (estimated from a 2,6-Di-tert-butyl-4-methylpheno (BHT) internal standard and adjusted for molecular mass);
(B) percent composition of dimethyl acetal aldehydes and major fatty acid classes in the lipid extract, as well as the estimated quantity of eicosapentanoic (EPA) and
docosahexanoic (DHA) per 100g tissue for each seafood.
(A) Fatty Acid Trivial Name Octopus tetricus Sepioteuthis australis Sardinops sagax Salmo salar Penaeus plebejus
Flesh Viscera Flesh Head Flesh Viscera & Head Flesh Head Flesh Head & Viscera
Saturated Fatty Acids (SFAs)
C12:0 Lauric 0.7 0 0 0 0.8 0.8 0.8 0.8 0.7 0
C13:0 tridecanoic 0 0 0 0 0.7 0.8 0 0 0 1.6
C14:0 myristic 43.0 20.0 11.3 14.8 57.8 59.7 16.5 20.1 17.8 16.1
C15:0 pentadecanoic 4.1 4.6 4.2 5.9 5.0 6.0 1.6 2.3 5.7 41.0
C16:0 palmitic 146.9 132.0 160.9 176.4 163.1 173.0 142.9 132.2 121.8 112.3
C17:0 heptadecanoic 8.0 14.0 11.1 11.6 65.6 6.9 3.1 4.0 7.4 26.0
C18:0 Stearic 43.7 69.1 69.4 67.2 34.6 37.0 40.1 39.4 39.2 44.5
C20:0 arachidic 3.6 4.1 1.5 1.5 4.5 4.8 0.8 0.8 1.5 3.2
C21:0 henicosanoic 0.7 0 0.8 0 0.8 0.8 0.8 0.8 3.1 21.4
C22:0 Behenic 2.2 2.5 1.6 2.4 2.4 1.7 0.9 0.8 1.6 3.4
C23:0 tricosanoic 0 0 0 0 0 0 1.0 0.9 0.9 1.9
C24:0 lignoceric 6.2 2.6 1.6 4.2 0.8 0.9 0.9 0.9 0.8 1.7
Monounsaturated Fatty Acids (MUFAs)
C14:1 myristoleic 6.2 2.3 0 0 1.5 1.5 1.6 1.5 0.7 2.3
C15:1 pentadecanoic 0.7 1.5 0 0 0.7 0.8 0.8 0.7 0.7 1.5
C16:1 palmitoleic 44.1 22.5 5.6 10.9 59.4 60.7 48.5 42.3 39.8 36.8
C17:1 heptadecanoic 0.7 1.5 0.7 2.2 0.7 1.5 2.3 2.2 7.0 50.6
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Table 1. Cont.
C18:1n9t elaidic 2.1 3.1 1.4 3.0 0.7 0.8 0.8 0.7 1.5 3.9
C18:1n9c oleic 42.2 43.7 16.7 55.9 50.3 54.2 301.9 261.7 230.3 93.4
C20:1n9 eicosenoic 19.2 14.4 12.6 0 3.8 3.9 15.6 16.8 16.3 8.0
C22:1n9 erucic 8.2 7.6 1.6 4.0 9.5 9.1 4.3 4.8 5.5 5.0
C24:1n9 nervonic 5.3 6.0 1.6 2.5 4.8 5.0 1.7 2.4 3.2 4.3
Polyunsaturated Fatty Acids (PUFAs)





C18:2n6c  Linoleic (LA)  12.3  8.5  2.8  0  15.2  0.8  82.8  76.3  67.2  20.8 
C18:3n6  Ƴ‐linolenic (GLA)  1.4  5.4  0.7  11.2  2.2  2.3  1.6  2.2  2.2  1.5 
C18:3n3  α‐linolenic (ALA)  10.6  4.7  0.7  2.2  13.9  14.5  10.3  8.9  8.6  3.1 
C20:2  eicosadienoic  1.4  5.5  2.2  12.2  1.5  1.6  4.8  7.5  6.6  6.3 
C20:3n3  eicosatrienoic  2.2  3.3  2.3  4.8  3.1  3.3  4.2  4.7  5.4  5.0 
C20:4n6  arachidonic (ARA)  21.6  56.7  77.1  63.2  11.4  12.0  4.8  7.0  10.5  34.0 
C20:5n3  eicosapentanoic (EPA)  120.3  107.0  62.5  53.6  123.2  125.6  14.0  19.6  26.2  75.3 
C22:2  docosadienoic  1.5  0.9  1.6  0  0.8  0.8   0  0.8  0.8  1.7 
C22:5n3  docosapentanoic (DPA)  24.4  22.9  10.1  7.9  18.1  18.0  7.5  12.2  14.4  33.8 
C22:6n3  docosahexanoic (DHA)  141.9  192.9  229.8  205.7  105.1  111.0  48.0  50.7  51.9  66.7 
(B) Fatty Acid  Trivial Name 
Octopus tetricus  Sepioteuthis australis  Sardinops sagax  Salmo salar  Penaeus plebejus 
Flesh  Viscera   Flesh  Head  Flesh  Viscera & Head  Flesh  Head  Flesh  Head & Viscera 
Dimethyl Acetal Aldehydes 
 dimethyl acetal octadecan‐1‐al  0  2.5  3.0  2.9  0  0  0  0  0  0 
 dimethyl acetal nonadecan‐1‐al  3.3  4  1.4  1.8  3.6  3.7  3.4  3.6  3.9  3.0 
Categories 
SFAs  25.5  24.9  26.2  28.4  27.7  29.2  20.9  20.3  20.0  27.3 
MUFAs  12.8  10.3  4.0  7.8  13.1  13.8  37.8  33.3  30.5  20.6 
PUFAs  33.7  40.8  39.0  36.1  29.4  29.0  17.9  19.0  19.3  24.8 
Total ω‐3  29.9  33.1  30.5  27.4  26.3  27.2  8.4  9.6  10.7  18.4 
Total ω‐6  3.5  17.1  8.6  7.4  2.9  1.5  9.1  8.5  8.0  5.6 
Total ω‐9  15.0  7.5  3.4  6.5  6.9  7.3  32.4  28.6  25.7  11.5 
Total unidentified  24.2  17.6  26.4  23.0  26.1  24.3  20.0  23.8  26.2  24.3 
Saturated/unsaturated ratio  0.6  0.5  0.6  0.6  0.7  0.7  0.4  0.4  0.4  0.6 
ω‐6/ω‐3 ratio  0.1  0.2  0.3  0.3  0.1  0.1  1.1  1.0  0.7  0.3 
EPA per 100 g tissue  64.2  395.7  88.7  99.3  1845.5  2972.5  104.2  238.5  29.9  138.2 
DPA per 100 g tissue  13.1  84.7  14.3  14.6  268.8  426.0  55.8  148.5  16.4  62.0 
DHA per 100 g tissue  75.7  713.4  326.0  381.2  1560.7  2627.0  357.2  617.0  59.1  122.4 
- 1.4 5.4 0.7 11.2 2.2 2.3 1.6 2.2 2.2 1.5
C18:3n3 α-linolenic (ALA) 10.6 4.7 0.7 2.2 13.9 14.5 10.3 8.9 8.6 3.1
C20:2 eicosadienoic 1.4 5.5 2.2 12.2 1.5 1.6 4.8 7.5 6.6 6.3
C20:3n3 eicosatrienoic 2.2 3.3 2.3 4.8 3.1 3.3 4.2 4.7 5.4 5.0
C20:4n6 arachidonic (ARA) 21.6 56.7 77.1 63.2 11.4 12.0 4.8 7.0 10.5 34.0
C20:5n3 eicosapentanoic (EPA) 120.3 107.0 62.5 53.6 123.2 125.6 14.0 19.6 26.2 75.3
C22:2 docosadienoic 1.5 0.9 1.6 0 0.8 0.8 0 0.8 0.8 1.7
C22:5n3 docosapentanoic (DPA) 24.4 22.9 10.1 7.9 18.1 18.0 7.5 12.2 14.4 33.8
C22:6n3 docosahexanoic (DHA) 141.9 192.9 229.8 205.7 105.1 111.0 48.0 50.7 51.9 66.7
(B) Fatty Acid Trivial Name Octopus tetricus Sepioteuthis australis Sardinops sagax Salmo salar Penaeus plebejus
Flesh Viscera Flesh Head Fl sh Viscera & Head Flesh Head Flesh Head & Viscera
Dimethyl Acetal Aldehydes
dimethyl acetal ct - - l 0 2.5 3.0 2.9 0 0 0 0 0 0
dimethyl acetal nonadecan-1-al 3.3 4 1.4 1.8 3.6 3.7 3.4 3.6 3.9 3.0
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Table 1. Cont.
Categories
SFAs 25.5 24.9 26.2 28.4 27.7 29.2 20.9 20.3 20.0 27.3
MUFAs 12.8 10.3 4.0 7.8 13.1 13.8 37.8 33.3 30.5 20.6
PUFAs 33.7 40.8 39.0 36.1 29.4 29.0 17.9 19.0 19.3 24.8
Totalω-3 29.9 33.1 30.5 27.4 26.3 27.2 8.4 9.6 10.7 18.4
Totalω-6 3.5 17.1 8.6 7.4 2.9 1.5 9.1 8.5 8.0 5.6
Totalω-9 15.0 7.5 3.4 6.5 6.9 7.3 32.4 28.6 25.7 11.5
Total unidentified 24.2 17.6 26.4 23.0 26.1 24.3 20.0 23.8 26.2 24.3
Saturated/unsaturated ratio 0.6 0.5 0.6 0.6 0.7 0.7 0.4 0.4 0.4 0.6
ω-6/ω-3 ratio 0.1 0.2 0.3 0.3 0.1 0.1 1.1 1.0 0.7 0.3
EPA per 100 g tissue 64.2 395.7 88.7 99.3 1845.5 2972.5 104.2 238.5 29.9 138.2
DPA per 100 g tissue 13.1 84.7 14.3 14.6 268.8 426.0 55.8 148.5 16.4 62.0
DHA per 100 g tissue 75.7 713.4 326.0 381.2 1560.7 2627.0 357.2 617.0 59.1 122.4
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Table 2. Cytotoxicity and anti-inflammatory activity of the lipid extracts from various tissues of commercial seafood species, as well as two commercially available
marine oils, calculated from the average of three repeat assays.
Organism Extract 3T3 ccl-92 FibroblastsViability at 50 µg/mL
RAW 264.7 Macrophages







Viscera 100% 100% 64.6 51.0
Flesh 100% 100% 71.2 71.0
Sepioteuthis australis
(Squid)
Head 100% 100% 91.1 67.7
Flesh 100% 100% 114.2 78.8
Sardinops sagax
(Australian Sardine)
Viscera/head 100% 100% 84.6 71.1
Fillet 100% 100% 66.5 147.7
Salmo salar
(Salmon)
Head 100% 100% 97.3 85.8
Fillet 100% 100% 157.9 157.1
Penaeus plebejus
(School Prawn)
Head/viscera 100% 100% 88.0 71.2
Body 100% 100% 306.4 201.7
Euphausia superba Krill Oil 100% 100% 337.8 99.8
Perna canaliculus
(NZ Green-Lipped Mussel) Oil (Lyprinol) 100% 100% No detectable activity >> max test dose 587.9
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2.3. NO Inhibition
Lipid extracts from all Australian seafood organisms demonstrated significant NO inhibition in
LPS-stimulated RAW 264.7 cells compared to the solvent positive control, except the lipid extract from
school prawn bodies, which only showed weak NO inhibition (Supplementary Figure S1 and Table 2).
Lipid extracts from the octopus showed strong NO inhibition with the lowest IC50s of 65 µg/mL.
The lipid extracts from the waste by-products showed higher NO inhibition (lower IC50s) than the
more commonly consumed flesh for octopus, squid, salmon, and prawns. All of the Australian seafood
lipid extracts were active at much lower concentrations than the reference nutraceutical oils, Lyprinol
and Deep Sea Krill oil, at the maximum concentration (Table 2). In fact, Lyprinol showed no inhibition
of NO in this assay at the maximum solubility.
Multivariate RELATE analysis using a Spearman rank correlation demonstrated a significant
relationship between NO inhibition and fatty acid composition (Rho = 0.302, p = 0.0477,
9999 permutations). BEST analysis revealed that a combination of four fatty acids explained the greatest
amount of variation in NO inhibiting activity, with a correlation coefficient of 0.428. NO inhibition
correlated with lower levels of oleic acid (C18:1) and higher levels of C18:3n-6, C20:2 and C22:2.
Univariate correlations to investigate the relationship between IC50 for NO and the amount of particular
fatty acids in the extracts revealed different trends depending on the fatty acid class (Supplementary
Figure S2). Negative relationships (i.e., lower IC50 at higher concentrations = stronger activity) were
observed for total SFAs (R2 = 0.4) and PUFA (R2 = 0.3), as well asω-3 PUFAs (R2 = 0.3), EPA (R2 = 0.4),
and to a lesser extent, DHA (R2 = 0.2). Conversely, MUFAs showed a positive relationship (higher
IC50s = weaker activity) (R2 = 0.3), along withω-9 FAs (R2 = 0.3). Surprisingly NO activity increased
with higher SFA:UFA ratios (R2 = 0.4), driven largely by inactive MUFAs, but decreased with higher
ω-6:ω-3 ratios (R2 = 0.3), as expected. There was no relationship between NO inhibitory activity and
the amount ofω-6 PUFAs, theω-3 DPA, or unidentified components in the extracts (Supplementary
Figure S2).
2.4. TNF-Alpha Inhibition
Lipid extracts from all the seafood samples demonstrated significant TNFα down-regulatory
effects reducing the levels of TNFα in the RAW 264.7 supernatant (Supplementary Figure S3, Table 2).
Octopus viscera again showed the lowest IC50 (51 µg/mL), whereas the body of prawns had the
highest IC50 at ~200 µg/mL. The extract from seafood by-products showed greater TNFα inhibition
than the edible flesh for all species (Table 2), and this was most noticeable in prawns, with an IC50
nearly three times lower in the heads and viscera that are routinely discarded in Australia. The fish
viscera and heads were approximately twice as active as the fillets.
There was a significant correlation between NO inhibition and TNFα inhibition (R2 = 0.631),
although the Australian sardine fillet had lower TNFα activity than would have been predicted
from the NO inhibition. Multivariate RELATE analysis revealed a marginally significant relationship
between TNFα inhibition and fatty acid composition (Rho = 0.269, p = 0.058, 9999 permutations).
BEST analysis identified only two fatty acids, with a correlation coefficient of 0.334. TNFα inhibition
was weakly correlated with lower levels of linolenic acid (C18:2) and higher levels of stearic acid
(C18:0). Univariate correlations investigating the relationship between IC50 for TNFα and the amount
of particular fatty acids in the extracts (Supplementary Figure S4) revealed similar trends to NO
inhibition (Supplementary Figure S2). Decreasing TNFα IC50 with higher quantities were observed for
total SFAs (R2 = 0.3) and PUFA (R2 = 0.4), as well asω-3 PUFAs (R2 = 0.4), DHA (R2 = 0.3), and to a
lesser extent, EPA (R2 = 0.2). MUFAs again showed the reverse trend, along withω-9 FAs (R2 = 0.3).
TNFα IC50 decreased with higher SFA:UFA ratios (R2 = 0.2), but increased with higher ω-6:ω-3 ratios
(R2 = 0.2). There was again no relationship between TNFα IC50 inhibitory activity and the amount of
ω-6 PUFAs, theω-3 DPA, or unidentified components in the extracts (Supplementary Figure S2).
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3. Discussion
This study demonstrates the quality and anti-inflammatory activity of lipids extracted from
different Australian seafood. Seafood is known to be high in PUFAs, which have been previously
associated with anti-inflammatory activity. All of the extracts tested in this study contain a high
content of PUFAs, with ω-6/ω-3 ratios less than one. Simopoulos [44] found that lower ratios are
desirable for reducing the risk of many chronic diseases, with ratios < 4:1 reducing mortality from
chronic disease, and ratios less than 3:1 suppressing inflammation due to arthritis. We found that
lower ω-6/ω-3 ratios correlated with higher NO and TNFα inhibitory activity across a range of
seafood extracts. Furthermore, Western diets typically contain excessive levels of saturated fats and
omega 6 fatty acids, which promote the pathogenesis of many diseases, including inflammatory
conditions [44]. Our lipid extracts from Australia seafood all had saturated to unsaturated fatty
acid ratios of less than 1, but higher amounts of MUFAs rather than SFAs were related to lower
NO and TNFα inhibitory activity. Overall, the entire fatty acid composition appears to influence
anti-inflammatory activity in vitro. Nevertheless, all of our extracts provided a good source ofω-3 fatty
acids and significantly inhibited LPS stimulated NO and TNFα production by macrophages in vitro.
This indicates the potential to value-add the Australian seafood industry based on high-quality marine
oils with anti-inflammatory activities.
Anti-inflammatory fatty acids were not only found in the flesh that is normally consumed in
Australian seafood, but are also present in high quantities in unprocessed parts like the head and
viscera. In fact, the viscera and heads produced a higher yield of oils and contained higher quantities
of commercially important long-chainω-3 PUFAs EPA, DPA, and DHA with known healthy attributes
for seafood consumers. The yields of these ω-3 PUFAs in the under-utilized/non-processed parts
were substantially higher than in the edible flesh for most species (e.g., ten times the DHA in octopus
viscera compared to flesh; four times the amount of EPA in prawn heads compared to flesh; and nearly
double the EPA, DPA, and DHA in salmon heads and sardine viscera/heads compared to the flesh).
This data is consistent with previous studies which have demonstrated high-quality fatty acid profiles
in the uneaten tissues of mackerel tuna fish Euthynnus affinis, ray-finned fish Sardinella lemuruand, and
Alaska pink salmon Oncorhynchus gorbuscha [30,31,45]. Overall the yields of EPA and DHA are similar
to the range previously reported for mollusks, fish, and crustaceans (e.g., Reference [46]), although
the Australian sardine is particularly notable for containing over 1000mg/100g tissue of both EPA
and DHA in both the flesh and viscera. Australian seafood waste streams could therefore be used
to generate a sustainable source of high-value marine lipids if they can be rapidly processed in a
centralized facility to prevent oxidation and degradation.
All the lipid extracts from Australian seafood tested in this study showed significant inhibition
of NO and TNFα, except those from the body of school prawns. As a neurotransmitter, NO is a
potent inflammatory mediator, as well as playing a role in wound healing and maintaining blood
pressure [47]. However, there are many diseases associated with the overproduction of NO, including
liver cirrhosis, rheumatoid arthritis, infection, autoimmune diseases, and diabetes [48]. Similarly, TNFα
is an important pro-inflammatory mediator that can lead to damaging effects, including neuropathic
pain, when over-expressed [49]. Inflammation and neuropathic pain are complex problems involving
many mediators and coupled signaling pathways which reduce the effectiveness of single compounds
for drug development [49]. Natural extracts that contain a mixture of potential inhibitors of inducible
NO Synthase (iNOS), TNFα expression, and other inflammatory pathway modulators might be
effective for controlling chronic inflammation. For example, studies on the NZ Green-lipped mussel
extract Lyprinol®, in a rat model for arthritis, have demonstrated that it modulates inflammatory
cytokines (TNFα, IL-6, IL-1α, and IL-γ) and decreases the synthesis of some proteins associated
with inflammation, whilst increasing malate dehydrogenase synthesis, which is related to glucose
metabolism [50]. The effects on regulatory proteins were proposed to reduce energy for MHC-1
activation as a novel mechanism of action with anti-inflammatory efficacy at lower doses than other
fish oil preparations. Lyprinol is a patented combination of 50 mg of PCSO-524® (lipid extract
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from P. canaliculus), 100 mg of a proprietary oleic acid blend, and 0.225 mg of vitamin E, so the
ω-3 fatty acids in this mussel lipid extract may act synergistically with the anti-oxidant Vitamin
E. Similarly, krill oil contains the antioxidant astaxanthin which can prevent lipid peroxidation,
thus preserving of the ω-3 fatty acids EPA and DHA, in addition to acting directly on a number
of biomarkers [51]. Krill oil has been shown to modulate cytokines, lipidogenesis, lipid peroxide,
oxidative enzymes, glucose metabolism, and the endocannabinoid system in a range of animal
studies [52]. It is possible that some of the unidentified components in our extracts have anti-oxidant
activity and/or immunomodulatory activity that complements or enhances the activity ofω-3 fatty
acids. Further in vivo studies investigating a range of anti-inflammatory markers and modulators
will be required to establish the mechanism of action and novel potential of these Australian seafood
lipid extracts.
The anti-inflammatory effects of fish oils and krill oil are typically attributed to long chainω-3
PUFAs [14,52]. Similarly, we found a correlation between the amount ofω-3 PUFAs in the extracts and
the IC50s for both LPS stimulated NO and TNFα inhibition in RAW264.7 macrophages. In particular,
the concentrations of both EPA and DHA were found to correlate with higher activity, but with EPA
showing a stronger relationship with NO inhibition and DPA explaining more of the variation in
TNFα inhibition. Previous studies on pure DHA and EPA have confirmed that these ω-3 PUFAs
strongly inhibit NO production (IC50 < 25 µM) [53] and inducible NO synthase in LPS stimulated
RAW264 macrophages (DHA at 30µM and EPA at 60 µM) [54]. Both EPA and DHA (100 µM) have
also been shown to reduce TNFα secretion in LPS stimulated RAW264.7 cells after 24 hr exposure to
100 µM [55], and they significantly inhibit the secretion and transcription of TNFα in LPS stimulated
THP-1 macrophages at 25 mM [56]. These studies lend support to the idea that EPA and DHA
are contributing to the in vitro anti-inflammatory activity in our extracts, however, without further
purification and testing against the pure compounds, we cannot conclude that there are no other
factors involved. Indeed, higher concentrations of saturated fatty acids were also found to correlate
with NO and TNFα inhibition, and our multivariate correlations indicate that the overall composition
of fatty acids is important, along with potentially unidentified factors.
In this study, lipid extracts from the two cephalopod mollusks contained the highest proportion
ofω-3 PUFAs and were associated with relatively high NO and TNFα inhibition. This supports the
use of the flesh from octopus (Zhang Yu) and squid (Qiang Wu Zei) in traditional Chinese Medicine for
inflammatory conditions [36]. Our comprehensive review of the anti-inflammatory, wound healing,
and immunomodulatory activity of mollusks [36] found no previous in vitro studies on cephalopod
extracts, and only a handful of in vivo animal models that have tested the ink and melanoprotein of
squid [57,58]. Nevertheless, one previous study found that cuttlefish (Ommastrephes bartrranii) liver
oil significantly reduced formalin and carrageenan-induced paw edema in rats fed 1% cuttlefish liver
oil for 45 days [59]. We found that the cephalopods produce a fairly low yield of oil in comparison
to oily fish, and consequently, they had lower overall amounts of EPA, DPA, and DHA per mg of
tissue. This suggests the cephalopods may not be as good a functional food for dietary intake ofω-3
PUFAs based on the mass obtainable from the wet weight of edible tissue as compared to some other
seafood, such as the Australian sardines, which have very high yields of ω-3 PUFAs in their flesh.
However, the viscera and heads of octopuses and squids produce a significant waste stream that could
be value-added based on their high-quality anti-inflammatory oils. For example, a large proportion
of Southern jig squid fishery is sold as processed tubes in Australia, generating approximately 48%
viscera as waste from ~1000 t annual harvest [60]. This justifies further investigation into cephalopod
lipid extracts for anti-inflammatory applications.
The fatty acid profiles of the cephalopod and sardine lipid extracts are dominated by ω-3
PUFAs, whereas the salmon and prawns contain relatively high MUFA and ω-9 PUFAs. The high
NO activity of sardine and cephalopod extracts reflects their richness in ω-3 fatty acids, especially
DPA, DHA, and EPA, which are arguably the healthiest PUFAs [12,23,61]. The main ingredients of
the well-known anti-inflammatory nutraceutical Lyprinol® and Biolane®, lipid extracts from the New
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Zealand green-lipped mussel (GMLE) Perna canaliculus, are long chainω-3 PUFA. The percent of the
ω-3 PUFA in GMLE is about 37.1% of the total fatty acids [40]. A similar proportion of ω-3 PUFAs
was found in the cephalopod mollusk extracts in this study. Interestingly, however, the different levels
ofω-3 fatty acids in the various seafood extracts were not found to correlate directly with either NO
or TNFα inhibitory concentrations in this study. Rather, lower levels of the MUFA oleic acid and
higher levels of theω-6 acids gamma-linolenic (C18:3), eicosadienoic (C20:2) and docosadienoic (C22:2)
correlated with higher NO activity, whereas lower levels of linolenic (C18:2) and higher levels of the
SFA stearic acid (C18:0) explained more of the variation in TNFα inhibitory concentrations. This implies
that the overall composition of fatty acids in seafood oils could influence the anti-inflammatory activity,
with particular fatty acids having either beneficial or antagonistic effects. This may help explain the
variable outcomes from clinical trials on the use of fish oils for some inflammatory conditions [62,63].
The minimal anti-inflammatory activity detected in our prawn flesh extract was similar to that
observed for a commercial krill oil in the same assays. The fatty acid composition of our prawn extracts
was similar to that previously reported for a commercial krill oil (10% ω-3 PUFAs, 14% ω-6 PUFAs
and 35% MUFAs), which was found to significantly modulate inflammation and lipid metabolism in
mice transgenic for TNFα [33]. Antarctic krill oil has also been shown to inhibit LPS-induced iNOS
in a rodent model [64] and to protect against rheumatoid arthritis in mouse models, but without
effects on serum cytokines [35]. Further research on Penaeid extracts is therefore justified despite
the relatively low in vitro activity. In particular, the waste streams from aquacultured prawns can be
sustainably produced in comparison to wild harvested krill, although their fatty acid compositions
could be impacted by an artificial diet [65].
Lyprinol®, the anti-inflammatory nutraceutical composed of lipid extracts from the Green-lipped
mussel Perna canaliculus, was also used as a reference drug but did not show detectable inhibition
of NO and TNFα in our in vitro assays. Green-lipped mussel extracts have been previously found to
suppress iNOS expression and inhibit NO production in LPS-induced RAW264.7 cells by regulating
nuclear factor kappa B [66], as well as inhibiting TNFα in LPS-stimulated human THP-1 monocytes [67].
Therefore, the lack of activity in both the commercial marine oils we tested is likely due to their relative
insolubility in ethanol as a result of product formulation. Furthermore, in vitro assays do not always
provide a good predictor of in vivo activity. Nevertheless, given the wealth of evidence relating to the
beneficial effects of ω-3 PUFAs in clinical trials, the preliminary in vitro anti-inflammatory activity
observed here, along with the beneficial fatty acid composition of Australian seafood extracts, justifies
further research to value-add the industry by developing a sustainable supply of high-quality fish oil.
4. Materials and Methods
4.1. Chemicals and Reagents
Escherichia coli LPS (O128:B12, Sigma-Aldrich, Castle Hill, Australia), sulfanilic acid, N-(1-Naphthyl)
ethylenediamine (NED), 85% orthophosphoric acid sodium nitrite (NaNO2), and HPLC grade solvents
were obtained from Sigma Aldrich (St. Louis, MO, USA). The mouse TNFα ELISA kit was purchased
from BD biosciences (Sparks, MD, USA). Penicillin–streptomycin solution, Dulbecco’s Modified
Eagle’s Medium (DMEM), fetal bovine serum (FBS), sodium pyruvate, and L-glutamine were from Life
Technology Australia (Mulgrave, VIC, Australia). The two cell lines, RAW264.7 mouse macrophages
and 3T3 Swiss albino (ATCC® CCL92™) cell lines, were purchased from the American Type Culture
Collection (ATCC®, Manassas, VA, USA).
4.2. Sample Collection
Fresh seafood used in this study including octopus (Octopus tetricus n = 3), Australian sardine
(Sardinops sagax n = 4), salmon (Salmo salar n = 3), school prawn (Penaeus plebejus, n = 12), and squid
(Sepioteuthis australis n = 3) were purchased fresh from Ballina seafood co-op., Ballina, Australia.
Salmon and squid viscera are processed during harvesting to prevent degradation and fouling of the
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prime edible flesh; however, the heads of these organisms are still available as a waste stream. All other
species were obtained whole and the typically consumed flesh was separated from the waste streams,
including internal organs (viscera) and heads. Lyprinol (BLACKMORES®, Alexandria, Australia) and
Krill oil (Swisse, Collingwood Melbourne, Australia) were purchased from a local pharmacy.
4.3. Lipid Extraction
Extracts from the cephalopods, O. tetricus and S. australis, included the tentacles and mantle tissue
(edible flesh) and body viscera, comprised of the gastrointestinal tract and other internal organs for
O. tetricus and just the heads for S. australis. Extracts from the fish included flesh fillets and viscera,
including heads from S. sagax, and just the head from S. salar. The head with viscera (waste) and body
(edible flesh) were also extracted from the school prawn Penaeus plebejus. Lipids were extracted as
above using a solvent to tissue ratio of 19 mL final volume for every 1 g tissue.
The solvent homogenates were vacuum filtered through Whatman paper (No. 1) into separating
funnels. Saturated NaCl solution (6.2 M) was added to the solvent phase to a final ratio of 8:4:3
(Chloroform: methanol: NaCl solution). The organic phases were collected and the solvent evaporated
on a rotary evaporator (Rotavapor® R-114; BÜCHI Labortechnik AG, Flawil, Switzerland). Extracted
lipids were transferred into glass vials, dried under a stream of nitrogen gas, weighed on an analytical
balance to calculate yield per g tissue, and then covered and stored in minimal hexane at −80 ◦C
until required.
4.4. Fatty Acid Methyl Ester (FAME) Analysis
Subsamples of 200 µL of foot and viscera lipid extracts from all species were placed in 10 mL
pyrex glass vials for derivitization. NaCl in methanol solution (0.5 M, 1.5 mL) was added under
nitrogen gas, capped and shaken for 10 secs. Samples were then heated at 100◦C for 10 min in a dry
block and cooled. Two mL of 14% Boron trifluoride in methanol was added and bubbled with nitrogen
gas for 8 s, then placed in a 100 ◦C dry block for 30 min. After cooling, 1 mL of hexane containing 1 µg
2,6-Di-tert-butyl-4-methylphenol (BHT) was added, and samples were shaken for 30 s. Saturated NaCl
solution (5 mL) was added and the samples were shaken to create an upper lipid layer, which was
collected and stored at −80 ◦C for FAMEs and GC-MS analysis.
FAMEs were analyzed using a GC (Agilent 6890N, Santa Clara, CA, USA) coupled to an
Agilent 6890 flame ionization detector (FID) using a BPX 70 capillary column (70% cyanopropyl
polysilphenylene-siloxane, 50 m length, 0.22 mm internal diameter and 0.25 µm thickness). The FID
was operated at 260 ◦C and the split injector was maintained at 230 ◦C. High-purity helium was used
as the carrier gas and maintained with a linear flux of 1 mL/min. The GC oven was held at 100 ◦C for
5 min and then raised to 240 ◦C at a rate of 5 ◦C/min. 1 µL of each subsample extract was injected
with a split ratio of 200:1 and a column flow of 1 mL/min.
FAMEs were identified by peak retention time and elution order and compared against a reference
FAMEs standard test mix (SUPELCO 37-Component FAME Mix CRM47885, Bellefonte, PA, USA)
and a marine test mix PUFA No.1 (Marine Source, Analytical Standards, Sigma-Aldrich, Castle
Hill, Australia). Some samples were further analyzed using an Agilent gas chromatography-mass
spectrometer (GC-MS) with an Agilent 5973 Mass Selective Detector to confirm the identity of the fatty
acids. The mass spectra were recorded at 70 eV ionization voltage over the mass range of 35–550 amu.
To facilitate the identification of DPA, which was not in the test mix, a soft ionization MS technique at
40 eV ionization voltage was employed to ionize the lipid molecules in the D. orbita samples without
causing extensive fragmentation. The spectrum was compared on MS databases (WILEY 275 online
and NIST98, Gaithersburg, MD, USA), along with retention times and elution order from extensive
literature searches including the American Oil Chemists’ Society. The relative composition of each
identified fatty acid was calculated by peak integration from the GC [68]. The concentration of each
fatty acid was estimated using BHT as an internal standard. In each sample, the area under the curve
for each fatty acid was calibrated against the peak area for BHT and adjusted for molecular weight,
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then scaled for the concentration on 1mg per g extract. For theω-3 PUFAs EPA, DHA, and DPA, we
also calculated the yield per 100 g of tissue by adjusting for the amount of crude lipid extract obtained
per g of tissue that was extracted.
4.5. Cell Lines and Cell Culture
The Murine RAW264.7 macrophages and 3T3 fibroblast cell lines were obtained from American
Type Cell Culture (ATCC). Both cell lines were maintained in 10% FBS supplemented DMEM, 100 µg/L
streptomycin, and 100 IU/mL penicillin at 37 ◦C and 5% CO2 atmosphere. Cells were passaged every
48–72 h [69].
4.6. Lipid Extract Preparation
Lipid extracts were dried under nitrogen gas flow before being weighed and dissolved in
HPLC-grade 100% ethanol. The stock solutions of the lipid extracts were diluted in color-free DMEM
before being added to the cell culture, and the final concentration of ethanol in all experiments was
around 0.35%. Stock solutions of the lipid extracts were prepared fresh on the day of the experiment
prior to addition to the cell culture. The solubility of all extracts in the cell cultures was confirmed under
an inverted microscope (200 and 400×). Each sample was tested in triplicate and each experiment was
repeated independently at least three times on different days.
4.7. Cytotoxicity Assay
Toxicity of the lipid extracts used in this study was assessed using a crystal violet cytotoxicity
assay as previously described by Feoktistova, et al. [70] using both the RAW 264.7 macrophages and
3T3 ccl-92 fibroblasts cell lines. Briefly, cells were seeded at a density of 2 × 104 cells/well in a 96-well
plate and then incubated for 18–24 h. Lipid extracts were added then and incubated for 24 h before the
media was aspirated and the cells washed twice in a gentle stream of water. Water was removed by
tapping the plate on a pile of paper towel followed by addition of 50 µL of 0.5% crystal violet staining
solution and incubated for 20 min at room temperature. The plate was then washed 4 times with water
and air dried for 2 h. Finally, 200 µL of methanol was added to each well and incubated for 20 min at
room temperature on a rocker. The optical density was then measured at 570 nm using Anthos Zenyth
200rt plate reader (Anthos Labtec Instruments, Heerhugowaard, Netherlands). Chlorambucil in a
gradient concentration was used as a positive control.
4.8. NO Inhibition Assay
The production of NO by LPS stimulated RAW 264.7 macrophages was measured in the cell
culture supernatant using the Greiss reaction method as previously described by Ahmad et al. [64].
In brief, RAW 264.7 macrophages were seeded at a density of 106 cell/mL and incubated overnight.
The following day, cells were incubated with different concentrations of the extracts 50, 25, 12.5, 6.25,
or 3.125 µg/mL 1 h prior to LPS stimulation. Twenty-four h after LPS stimulation, the supernatant
was collected, and an equal volume of supernatant and Greiss’ reagent was mixed in a 96 well plate
and incubated in dark for 10–15 min. Absorbance was read at 550 nm using an Anthos Zenyth 200rt
plate reader (Anthos Labtec Instruments, Heerhugowaard, Netherlands). Sodium nitrite was used
as a standard in this assay, and all assays were repeated in triplicate. The commercially available
marine nutraceuticals Lyprinol (BLACKMORES®, Sydney, Australia) and Deep Sea Krill oil (Swisse,
Collingwood, Australia) were used as reference anti-inflammatory nutraceuticals at the same test
concentrations. Dexamethasone at 2.5 µM concentration was used as a reference drug. All assays were
repeated three times.
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4.9. TNF Alpha Inhibition Assay
The levels of TNFα produced by LPS stimulated RAW 264.7 macrophages in the cell culture
supernatant were measured using a mouse TNFα ELISA kit (R&D Systems, Minneapolis, MN, USA)
and performed as per the manufacturer’s instructions. All extracts were tested in five different
concentrations 50 µg/mL, 25 µg/mL, 12.5 µg/mL, 6.25 µg/mL, and 3.125 µg/mL. Dexamethasone
was used as a reference anti-inflammatory drug, and untreated, stimulated cells (LPS + ethanol)
were used as a positive control. Absorbance was read at 450 nm using an Anthos Zenyth 200rt
plate reader (Anthos Labtec Instruments, Heerhugowaard, Netherlands). The commercially available
marine nutraceuticals Lyprinol® (BLACKMORES®, Alexandria, Australia) and Deep Sea Krill oil
(Swisse, Collingwood Melbourne, Australia) were used as reference anti-inflammatory nutraceuticals.
The assays were repeated in triplicate.
4.10. Statistical Analysis
PRIMER v 7 + PERMANOVA software (version 7, Primer-e, Albany, New Zealand) was used
to explore the multivariate differences in lipid profiles, and univariate analyses were used to test
differences in specific lipid classes and anti-inflammatory activity between the various seafood extracts.
Separate Euclidean distance similarity matrices were created for the fatty acid percent composition,
the composition of fatty acid classes, and the totals for each fatty acid class (SFA, MUFA, PUFA andω-3,
ω-6, n-9,ω-3:ω-6 and DMAAs), as well as the IC50 for NO inhibition and TNFα inhibition. Principle
Coordinate Ordination plots were generated on the fatty acid composition with vector overlay based
on Pearson’s correlation with a cut-off at r > 0.8 to identify which fatty acids contributed most to the
separation between samples.
To assess the relationship between fatty acid composition and NO inhibition or TNFα
inhibition, relate analyses were undertaken on PRIMER V7 using Spearman rank correlation and
9999 permutations. This was followed by a BIOENV stepwise model on the Euclidean distance
similarity matrix to identify which set of fatty acids explained the most variability for each of the
anti-inflammatory markers.
5. Conclusions
In conclusion, lipid extracts from Australian marine seafood were found to contain a high ratio of
unsaturated: saturated fatty acids and significant anti-inflammatory activity. The inhibition of NO and
TNFα in LPS stimulated macrophages was correlated with higher levels of SFAs and PUFA, and in
particular theω-3 PUFAs EPA and DHA, as well as with lower levels of MUFAs, thus indicating that
the overall composition of marine lipid extracts can influence the anti-inflammatory activity. High
valued marine oils rich in healthyω-3 PUFAs were not only demonstrated in the edible parts of seafood,
but the under-utilized components of these organisms showed similar if not higher proportions of
PUFAs and anti-inflammatory activity. In particular, the byproducts from cephalopod mollusks appear
to have good anti-inflammatory activity, with potential for the development of another high-quality
marine oil for nutraceutical applications. Further in vitro and in vivo studies are required to optimize
and develop the seafood waste stream as used for natural anti-inflammatory treatments.
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Figure S1: The NO inhibitory activity of lipid extracts from different seafood organisms; (A) Penaeus plebejus
(Australian school prawn), body flesh and head, including viscera; (B) Sardinops sagax (Australian sardine)
flesh and viscera, including heads; (C) Salmo salar (Atlantic salmon) flesh and heads; (D) Sepioteuthis australis;
(E) Octopus tetricus * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus the LPS + Solvent control. Figure S2:
Correlations between NO inhibitory activity (IC50) of lipid extracts and the amount of certain fatty acid classes
or ratios in different seafood organisms. Figure S3: The TNFα inhibitory activity of lipid extracts from different
seafood organisms; (A) Penaeus plebejus (Australian school prawn), body flesh and head, including viscera;
(B) Sardinops sagax (Australian sardine) flesh and viscera, including heads; (C) Salmo salar (Atlantic salmon) flesh
and heads; (D) Sepioteuthis australis; (E) Octopus tetricus * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus
the LPS + Solvent control. Figure S4: Correlations between the TNFα inhibitory activity (IC50) of lipid extracts
and the amount of certain fatty acid classes or ratios in different seafood organisms.
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